Helicobacter pylori eradication is recommended for early gastric cancer patients after resection.
Dr Cho and colleagues from Korea evaluated whether H. pylori eradication improves glandular atrophy and intestinal metaplasia in gastric cancer patients undergoing subtotal gastrectomy.
The research team performed a randomized, double-blind trial in a tertiary care setting.
Distal gastric cancer patients with H. pylori infection were randomized to receive proton pump inhibitor-based triple therapy or placebo.
|Specific clinical subtypes could improve classification of the disease |
|Alimentary Pharmacology & Therapeutics|
The histology was evaluated using the updated Sydney system before and at 36 months after surgery.
The endpoints were the comparison of atrophy and intestinal metaplasia score changes between the allocated groups and according to final H. pylori status.
Overall, 190 patients were randomized to the treatment and placebo groups.
The doctors undertook further research for lesser curvature of the corpus, mean atrophy and intestinal metaplasia scores did not differ between the treatment and placebo groups.
However, the H. pylori-eradicated patients had significantly lower mean scores than the H. pylori-persistent patients regarding atrophy and intestinal metaplasia.
The team noted that the percentage change from baseline was more marked in the H. pylori-negative than in the H. pylori-positive groups.
For greater curvature, mean atrophy score was lower in the H. pylori-negative group than in the H. pylori-positive group.
The team found that the percentage change was -36% vs. 86%.
Dr Cho's team concludes, "Helicobacter pylori eradication in gastric cancer patients is beneficial, as reflected by lower scores of atrophy and intestinal metaplasia at 36 months after subtotal gastrectomy."